Insider Selling: uniQure (NASDAQ:QURE) CFO Sells 10,438 Shares of Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 10,438 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the sale, the chief financial officer now owns 217,730 shares of the company’s stock, valued at approximately $2,240,441.70. This represents a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The shares were sold at an average price of $11.32, for a total value of $33,009.12.
• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The shares were sold at an average price of $10.70, for a total value of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total value of $13,559.80.

uniQure Price Performance

Shares of QURE opened at $12.51 on Friday. The business’s 50-day moving average is $14.59 and its two-hundred day moving average is $9.92. The company has a market capitalization of $609.77 million, a P/E ratio of -2.52 and a beta of 0.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its position in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the period. Tudor Investment Corp ET AL grew its position in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 1,371 shares during the period. Wells Fargo & Company MN grew its position in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares during the period. Northern Trust Corp grew its position in shares of uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after acquiring an additional 3,996 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on QURE shares. Mizuho increased their price objective on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. Wells Fargo & Company reduced their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of uniQure in a research note on Tuesday. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Finally, Stifel Nicolaus raised their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.